Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report

Durvalumab consolidation therapy is the standard treatment after concurrent chemoradiotherapy for patients with surgically unresectable stage IIIA (N2) non-small-cell lung cancer (NSCLC). Neoadjuvant therapy followed by surgery could reduce locoregional and distant recurrence and improve the surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Rui-Xia, Hei, Yue, Zhu, Wen-Ting, Wang, Qian-Rong, Zhang, Hong-Mei, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497472/
https://www.ncbi.nlm.nih.gov/pubmed/36135056
http://dx.doi.org/10.3390/curroncol29090487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497472/
https://www.ncbi.nlm.nih.gov/pubmed/36135056
http://dx.doi.org/10.3390/curroncol29090487

Ejemplares similares